Overview

The Division of Hematology-Research strives to be the leader in clinical and translational hematologic research, ultimately improving the diagnosis and treatment of all types of blood disorders, both cancerous and noncancerous.

Our team of physicians and scientists works together in disease-oriented groups, allowing focus on particular conditions while also leveraging multidisciplinary expertise through cross-collaborations. Each disease group consists of basic research scientists, translational research scientists and clinicians who work directly with patients.

Research in the Division of Hematology-Research is conducted at all three sites of the Mayo Clinic enterprise — Phoenix, Arizona; Jacksonville, Florida; and Rochester, Minnesota.

The division is closely aligned with the Hematologic Malignancies Program and its two related SPORES (Specialized Programs of Research Excellence). The program is part of Mayo Clinic Comprehensive Cancer Center, which has been designated by the National Cancer Institute (NCI) as a comprehensive cancer center — getting research funding support from the NCI and providing direct services to patients with cancer.

Investigators in the Division of Hematology-Research focus on the genetic, molecular and cellular basis of hematologic conditions and the translation of these findings into novel clinical trials and new therapeutic treatment options. Many of our investigators have research funding from the NCI, the National Institutes of Health, and private benefactors and foundations. They participate in an active clinical trials program and have published hundreds of journal articles detailing their research results. Our team also includes dozens of experts in treating blood cancers and noncancerous blood disorders, from the most common to very rare hematologic diseases.

Hematology research advances include:

• Virotherapy
• Immune checkpoint inhibitors
• CAR-T cell therapy

The close connection between clinical care and research at Mayo Clinic is driving treatment advances that will improve outcomes for patients with hematologic conditions.